Transcriptional Control of Proteases

  • H. Allgayer
  • E. Lengyel
  • D. D. Boyd
Part of the Cancer Metastasis — Biology and Treatment book series (CMBT, volume 4)


We now have a good knowledge of the trans -acting factors and cis elements involved in the regulation of protease expression in cancer. However, there are still issues which remain unanswered. For example, in many cancers, protease expression is not in the tumor cells but in the surrounding stromal cells. How then can this be explained if a variety of trans acting factors such as AP-1, NF-κB are constitutively active in the cancer cells. Future studies will have to address this question. It may very well be that the chromatin environment and epigenetic factors, such as methylation shown to regulate urokinase expression (Xing and Rabbani, 1999), play a crucial role in the regulation of gene expression and works in concert with the know trans acting factors to exert control of gene expression.


Transcription Factor Binding Site Phorbol Ester Protease Gene Protease Expression Transcription Factor Family Member 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999; 86: 2602–2611.CrossRefPubMedGoogle Scholar
  2. Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O, Boyd DD. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2α-related factor. J Biol Chem 1999a; 274: 4702–4714.PubMedCrossRefGoogle Scholar
  3. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (−152/−135) bound with Sp1. J Biol Chem 1999b; 274: 18428–18445.PubMedCrossRefGoogle Scholar
  4. Armstrong JA, Bieker JJ, Emerson WA. A SWI/SNF-related chromatin remodeling complex ERC1, is required for tissue-specific transcriptional regulation of EKLF in vitro. Cell 1998; 95: 93–104.CrossRefPubMedGoogle Scholar
  5. Armstrong JA, Emerson BM. Transcription of chromatin: these are complex times. Current Opinion in Genetics and Development 1998; 8: 165–172.CrossRefPubMedGoogle Scholar
  6. Aho S, Rouda S, Kennedy SH, Qin H, Tan EM. Regulation of human interstitial collagenase (matrix metalloproteinase 1) promoter activity by fibroblast growth factor. Eur J Biochem 1997; 247: 503–510.CrossRefPubMedGoogle Scholar
  7. Biggar SR, Crabtree GR. Continuous and widespread roles for the Swi-Snf complex in transcription. EMBO J 1999; 18: 2254–2264.CrossRefPubMedGoogle Scholar
  8. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene 1993; 8: 877–886.PubMedGoogle Scholar
  9. Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 1994; 9: 791–799.PubMedGoogle Scholar
  10. Chiu R, Angel P, Karin M. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell 1989; 59: 979–986.CrossRefPubMedGoogle Scholar
  11. Costa M, Shen Y, Maurer F, Medcalf RL. Transcriptional regulation of the tissue-type plasminogen activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen activator gene promoter. Eur J Biochem 1998; 258: 123–131.CrossRefPubMedGoogle Scholar
  12. Deng T, Karin M. c-Fos transcriptional activity stimulated by H-ras-activated protein kinase distinct from JNK and ERK. Nature 1995; 371: 171–175.ADSCrossRefGoogle Scholar
  13. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. Heterodimerization of c-jun with ATF-2 and c-fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 1995; 11: 365–376.PubMedGoogle Scholar
  14. de Launoit Y, Baert J, Chotteau A, Monte D, Defossez PA, Coutte L, et al. Structure-function relationships of the PEA3 group of ets-related transcription factors. Biochemical and Molecular Medicine 1997; 61: 127–135.PubMedCrossRefGoogle Scholar
  15. Edmead C, Kanthou C, Benzakour O. Thrombin activates transcription factors Sp1, NfkappaB, and CREB: importance of the use of phosphatase inhibitors in nuclear protein extraction for the assessment of transcription factor DNA-binding activities. Anal Biochem 1999; 275: 180–186.CrossRefPubMedGoogle Scholar
  16. El Kharroubi A, Piras G, Zensen R, Martin MA. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 1999; 18: 2535–2544.Google Scholar
  17. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A, Mackay AR. Transcriptional up-regulation of matrix-metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ 1999; 10: 353–367.PubMedGoogle Scholar
  18. Fini ME, Bartlett JD, Matsubara M, Rinehart WB, Mody MK, Rainville M. The rabbit gene for 92-kDa matrix metalloproteinase. Role of AP1 and AP2 in cell type-specific transcription. J Biol Chem 1994; 269: 28620–28628.PubMedGoogle Scholar
  19. Goodrich JA, Cutler G, Tjian R. Contacts in context: Promoter specificity and macromolecular interactions in transcription. Cell 1996; 84: 825–830.CrossRefPubMedGoogle Scholar
  20. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci (USA) 1999; 96: 4868–4873.ADSCrossRefGoogle Scholar
  21. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDA gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996; 271: 10672–10680.PubMedCrossRefGoogle Scholar
  22. Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990; 9: 2241–2246.PubMedGoogle Scholar
  23. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F. A novel complex between the p65 subunit of NF-kB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 1992; 11: 205–213.PubMedGoogle Scholar
  24. Himelstein BP, Lee EJ, Sato H, Seiki M, Muschel RJ. Transcriptional activation of the metrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene 1997; 14: 1995–1998.CrossRefPubMedGoogle Scholar
  25. Michael LF, Hiroshi A, Shulman AI, Kraus WL, Montminy M. The phosphorylation status of a cyclic AMP-responsive activator is modulated via a chromatin-dependent mechanism. Mol Cell Biol 2000; 20: 1596–1603.CrossRefPubMedGoogle Scholar
  26. Ibanez-Tallon I, Caretti G, Blasi F, Crippa MP. In vivo analysis of the state of the human uPA enhancer following stimulation by TPA. Oncogene 1999; 18: 2836–2845.PubMedCrossRefGoogle Scholar
  27. Karin M, Liu ZG, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240–246.CrossRefPubMedGoogle Scholar
  28. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270: 16483–16486.PubMedGoogle Scholar
  29. Kornberg R. Eukaryotic transcriptional control. Trends Biochem Sci 1999; 9: 46–49.CrossRefGoogle Scholar
  30. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem 1996; 61: 430–438.CrossRefPubMedGoogle Scholar
  31. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 1995a; 270: 23007–23012.CrossRefPubMedGoogle Scholar
  32. Lengyel E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer MJ, et al. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 1995b; 11: 2639–2648.Google Scholar
  33. Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J. Structural analysis and promoter characterization of membrane-type matrix metalloproteinase-1 (MT1-MMP). Gene 2000; 242: 75–86.CrossRefPubMedGoogle Scholar
  34. Merchiers P, Bulens F, De Vriese A, Collen D, Belayew A. Involvement of Sp1 in basal and retinoic acid induced transcription of the human tisue-type plasminogen activator gene. FEBS Lett 1999; 456: 149–154.CrossRefPubMedGoogle Scholar
  35. Mertens PR, Alfonso-Jaume MA, Steinmann K, Lovett DH. A synergistic interaction of transcription factors AP-2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J Biol Chem 1998; 273: 32957–32965.CrossRefPubMedGoogle Scholar
  36. Mohan R, Rinehart WB, Bargagna-Mohan P, Fini ME. Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling. J Biol Chem 1998; 273: 25903–25914.CrossRefPubMedGoogle Scholar
  37. Munaut C, Salonurmi T, Kontusaari S, Reponen P, Morita T, Foidart JM, Tryggvason K. The murine matrix metalloproteinase 9 gene. J Biol Chem 1999; 274: 5588–5596.CrossRefPubMedGoogle Scholar
  38. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991; 6: 1583–1593.PubMedGoogle Scholar
  39. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Dano K. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65: 57–62.CrossRefPubMedGoogle Scholar
  40. Novak U, Cocks G, Hamilton J. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Research 1991; 19: 3389–3393.PubMedCrossRefGoogle Scholar
  41. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP-1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997; 272: 18586–18594.CrossRefPubMedGoogle Scholar
  42. Pondel MD, Murphy S, Pearson L, Craddock C, Proudfoot NJ. Sp1 functions in a chromatin-dependent manner to augment human α-globin promoter activity. Proc Natl Acad Sci (USA) 1995; 92: 7237–7241.ADSCrossRefGoogle Scholar
  43. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eirksen J, Blasi F, Dano K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Amer J Pathol 1991; 138: 1059–1067.Google Scholar
  44. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Amer J Pathol 1993; 142: 359–365.Google Scholar
  45. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999; 274: 29130–29137.PubMedCrossRefGoogle Scholar
  46. Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Graeff H, Schmitt M. Inhibition of NF-kB-rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Research 1995; 23: 3887–3893.PubMedCrossRefGoogle Scholar
  47. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993; 8: 395–405.PubMedGoogle Scholar
  48. Sato H, Kita M, Seiki M. v-src activates the expression of 92-kDa type IV collagenase through the AP-1 site and the GT Box homologous to retinoblastoma control elements. J Biol Chem 1993; 268: 23460–23468.PubMedGoogle Scholar
  49. Smith CL, Hager GL. Transcriptional regulation of mammalian genes in vivo. J Biol Chem 1997; 272: 27493–27496.PubMedCrossRefGoogle Scholar
  50. Somasundaram K, Jayaraman G, Williams T, Moran E, Frisch S, Thimmapaya B. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2. Proc Natl Acad Sci (USA) 1996; 93: 3088–3093.ADSCrossRefGoogle Scholar
  51. Sumpio BE, Chang R, Xu WY, Wang X, Du W. Regulation of t-PA in endothelial cells exposed to cyclic strain: role of CRE, AP-2, and SSRE binding sites. Am J Physiol 1997; 273: C1441–C1448.PubMedGoogle Scholar
  52. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997; 57: 1199–1205PubMedGoogle Scholar
  53. Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression and protein analysis. J Biol Chem 1994; 269: 22958–22963.PubMedGoogle Scholar
  54. Tremble P, Damsky CH, Werb Z. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Cell Biol 1995; 129: 1707–1720.CrossRefPubMedGoogle Scholar
  55. Vignali M, Hassan AH, Neely KE, Workman JL. ATP-dependent chromatin-remodeling complexes. Mol Cell Biol 2000; 20: 1899–1910.CrossRefPubMedGoogle Scholar
  56. Versteege I, Sevenet N, Lange J, Rousseau-Merck M-F, Ambros P, Handgretinger R, Aurias A, Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394: 203–206.PubMedCrossRefGoogle Scholar
  57. Walter M, Hugel A, Huang H, Cavenee WK, Wiestler OD, Pietsch T, et al. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 1999; 59: 5608–5614.Google Scholar
  58. Wang F, Duan R, Chirgwin J, Safe SH. Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol 2000a; 24 193–202.PubMedCrossRefGoogle Scholar
  59. Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 2000b; 267: 3248–3254.PubMedCrossRefGoogle Scholar
  60. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998; 77: 128–137.CrossRefPubMedGoogle Scholar
  61. Westermarck J, Kähäri V-M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781–792.PubMedGoogle Scholar
  62. White L, Brinckerhoff CE. Two AP-1 elements in the collagenase (MMP-1) promoter have differential effects on transcription and bind JunD, c-Fos, and Fra-2. Matrix Biol 1995; 14: 715–725.CrossRefPubMedGoogle Scholar
  63. Xing RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: prole of DNA methylation. Int J Cancer 1999; 81: 443–450.CrossRefPubMedGoogle Scholar
  64. Xing X, Wang S, Xia W, Zou Y, Shao R, Kwong KY, et al. The Ets protein PEA3 suppresses Her2/neu overexpression and inhibits tumorigenesis. Nature Med 2000; 6: 189–195.PubMedCrossRefGoogle Scholar
  65. Yan S, Berquin IM, Troen BR, Sloane BF. Transcription of human cathepsin B is mediated by Sp family factors in glioma. DNA Cell Biol 2000; 19: 79–91.CrossRefPubMedGoogle Scholar
  66. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, D’Aiuto G, Stoppelli MP, Salvatore M. Co-ordinate up-regulation of Sp1 DNA-binding activity and urokinase-receptor expression in breast carcinoma. Cancer Res 2000; 60: 1546–1551.PubMedGoogle Scholar
  67. Xue Y, Wong J, Moreno GT, Young MK, Cote J, Wang W. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Molecular Cell 1998; 2: 851–861.CrossRefPubMedGoogle Scholar
  68. Yan C, Wang H, Toh Y, Boyd DD. Repression of 92 kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism which is both dependent and independent of histone deacetylation. J Biol Chem 2003; in press.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • H. Allgayer
    • 1
  • E. Lengyel
    • 2
  • D. D. Boyd
    • 3
  1. 1.Department SurgeryKlinikum Grosshadern Ludwig-Maximilians UniversityMunichGermany
  2. 2.Department of Obstetrics and GynecologyTechnical University of MunichMunichGermany
  3. 3.Department of Cancer BiologyM.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations